AGC Biologics Partners with Quell Therapeutics to Advance T-Regulatory Cell Therapies for Immune Disorders
Quell is working to create transformative treatments for immune and inflammatory disorders by using the unique properties of Tregs to restore balance in the immune system. Under this agreement, AGC Biologics' Milan Cell and Gene Center of Excellence is producing LVV material for Quell Treg cell therapy candidates. With the ProntoLVV platform process, AGC Biologics will integrate Quell's gene of interest into its standardized production protocols with off-the-shelf starting materials, offering flexibility for both suspension and adhesion systems. This approach helps ensure GMP readiness and a smoother transition to GMP manufacturing and clinical trials.
"Our ProntoLVV platform is well-suited to support Quell in advancing its Treg cell therapies toward clinical trials," said Luca Alberici, Executive Vice President, Global Cell & Gene Technologies, AGC Biologics. "By combining standardized processes with the strong technical expertise of our scientific teams at the Milan site, we will work closely with our partners at Quell to help them streamline the development of these therapies while delivering the high-quality lentiviral vector material essential for CTA/IND submissions."
"AGC Biologics provides the reliability, speed and efficiency we need as we prepare our Treg therapies for clinical trials," said Aaron Vernon, Chief Manufacturing Officer, Quell Therapeutics. "This partnership is critical as we work to address severe immune disorders and bring innovative treatments to patients. We are looking forward to working with the AGC Biologics team of experts to support our programs into clinical development."
The AGC Biologics Milan Cell and Gene Center of Excellence offers 30 years of experience in cell and gene therapy, with nine commercial approvals and hundreds of GMP batches produced successfully. The site holds commercial manufacturing authorizations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for viral vectors and cell therapies. The teams of experts there have a reputation for collaboration and working side-by-side with customers to find clinical, late-phase and commercial successes. AGC Biologics' Cell and Gene Technologies Division has a global network of facilities to help partners accelerate their drug development timelines while supporting the highest quality standards in the industry. Under this division's leadership, AGC Biologics is focused on making life-saving treatments more cost-effective and aims to be able to offer lentiviral vectors for commercial applications at a cost as low as 1,000 USD per patient.
With AGC Biologics' ProntoLVV platform, lentiviral vector production is now more streamlined. Standardized procedures reduce the amount of time needed while maintaining flexibility and include high-quality, ready-to-use packaging plasmids, a unique gene transfer system, and the necessary documentation to support regulatory submissions. ProntoLVV includes in-house analytics, and production is scalable, ensuring efficiency from early development all the way through GMP manufacturing and beyond.
AGC Biologics offers a comprehensive suite of services for viral vector-based therapies, from process development to commercial manufacturing.
About Quell Therapeutics:
Quell Therapeutics is a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system. The Company is leveraging its proprietary Foxp3 Phenotype Lock technology, unique multi-modular platform and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for persistence, potency and stability than earlier generations of Treg cell therapy approaches. Quell's lead candidate QEL-001 is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. Quell is also advancing additional programs in other autoimmune and inflammatory diseases. To learn more please visit www.quell-tx.com.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,800 Team Members worldwide. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250515626803/en/
Contacts
Media ContactNick McDonaldAGC Biologicsnmcdonald@agcbio.com
AGC Inc. Media Contactinfo-pr@agc.com
Luke Henry, Chief Business OfficerQuell TherapeuticsIR@quell-tx.com
Media: Mark Swallow, Sandi Greenwood, Erica HollingsworthMEDiSTRAVA Quell-Tx@Medistrava.com
Investors: Corey DavisLifeSci Advisorscdavis@lifesciadvisors.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 days ago
- Business Upturn
Concord Biotech successfully completes Russian GMP inspection at Dholka API facility
Concord Biotech is pleased to announce the successful completion of the Russian GMP (Good Manufacturing Practice) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility located in Dholka, Gujarat. The inspection was conducted from July 22, 2025, to July 25, 2025. In the exchagne filings, the company shared, 'We are pleased to announce the successful completion of the Russian GMP (Good Manufacturing Practice) inspection at our Active Pharmaceutical Ingredient (API) manufacturing facility located in Dholka, Gujarat. The inspection was conducted from July 22' 2025 to July 25' 2025.' This achievement underscores the company's commitment to upholding the highest standards of quality, safety, and regulatory compliance across all areas of its operations. It also reflects Concord Biotech's continued focus on meeting the rigorous requirements of global regulatory authorities. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Time Business News
3 days ago
- Time Business News
What to Look for When Buying Active Proteins Online?
Purchasing active proteins online sounds like a piece of cake- or on the contrary, it is not as simple as clicking 'buy now'. Most of the sellers claim they are high-purity and perform. But: Is protein really active? Do you have any confidence in the supplier? Do you pay to get results or fancy labels? The nature of such a specialized product as the PRL active protein means that the wrong decision can eat away at your whole project. And the protein is important whether it is used in research, biotechnology, or diagnostics. Therefore, when you want to buy active proteins online, hold on a bit and ask the right questions. So, here is how to select savvy and how to do that without making standard blunders and obtain proteins that will do as they are told. Not all proteins are the same. Some are used in diagnostics, others in signaling studies or drug development. Knowing why you need the protein is your first step. Ask yourself: Do I need the protein for in vitro or in vivo use? Should it be tagged or untagged? Is it for structure, function, or binding analysis? For instance, PRL active protein is often used for research in cancer signaling and cell regulation. Buying the wrong type or form will lead to inaccurate results. The company you buy from matters. A low-quality supplier may cut corners, affecting the performance of your protein, even if the label looks perfect. What to look for in a supplier: Criteria Why It Matters Reputation Trusted suppliers = reliable results Transparency Look for data on source & purification Quality Certifications ISO or GMP is a good sign Customer Support They should answer questions clearly Tip Avoid sites that don't show certifications or test results. A protein can be 98% pure but completely inactive. You need both purity and functionality. Things to Check: Does the site list biological activity (not just purity)? Are functional tests like ELISA or Western blot mentioned? Is PRL an active protein tested for actual phosphatase activity? Example: Protein Sample Purity Activity Assay Shown? Buy It? Sample A 97% Yes – ELISA verified ✅ Sample B 99% No data available ❌ Don't be fooled by purity alone—check if it actually works. The technical sheet is something you must read before placing an order. It provides important information, including ideal weight, buffer required, and storage requirements. The required information in the sheet: Storage conditions and temp Concentration and size of protein Reconstitution instructions Endotoxin content (in particular in vivo) Tip A good supplier will give you this file in advance; do not purchase without it. Even the best proteins lose value if they arrive damaged or warm. Many proteins—especially PRL active protein—require cold shipping. Things to confirm before checkout: Factor What to Look For Shipping method Dry ice or cold packs included Shipping time Fast, trackable delivery Storage instructions Provided upon delivery Yes, customer reviews count even in science. They will tell most of what is not told in product listings. Helpful signs in reviews: 'Worked exactly as expected' 'No activity detected' (red flag) 'Great for signaling assays' Reviews provide the real-life experience on the performance of protein in your labs. Low price doesn't always mean good value. If the protein doesn't work, you'll waste more money troubleshooting. Think about: Will they provide samples to purchase in large quantities? What is the policy of refund/replacement when inactive? Will you be experiencing frequent orders? Still unsure about which protein to choose? Just ask. A good supplier will happily guide you. Questions to ask: How was the activity checked? Is it devoid of endotoxin? Can I freeze it to -20℃ or even -80℃? Regarding product stability post-reconstitution, what is it? You do not purchase a product on your order of active proteins online, but you purchase results. A single errant decision can consume weeks of lab efforts, time, and money. And that is why it is worth looking a bit closer: Make up your mind as to what shape and purpose is good for you Purity checks, but more importantly, bio-activity checks Buy only from reputable open supply sources Always keep a check on handling, reviews, and documentation Whether it's PRL active protein or another specialized reagent, smart buying is about clarity, not guesswork. Ask questions, double-check specs, and never settle for less than quality. TIME BUSINESS NEWS
Business Wire
4 days ago
- Business Wire
Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease
HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) ('Coya' or the 'Company'), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the publication of a new research study, partially funded by Coya. The study, led by Drs. Aaron Thome, a scientific advisor to Coya, and Stanley H. Appel, the chairperson of Coya's Scientific Advisory Board, explores the role of immune dysfunction in the pathogenesis of PD. It was published in the scientific journal Frontiers of Immunology, which can be accessed here. PD is one of the most prevalent neurodegenerative disorders, marked by the progressive loss of dopaminergic neurons in the substantia nigra. This degeneration leads to motor symptoms such as tremors, rigidity, and bradykinesia, as well as non-motor symptoms, including cognitive impairment, autonomic dysfunction, and psychiatric disturbances. Peripheral immune dysfunction, characterized by altered cytokine levels and dysregulated immune cell function, appears to play a significant role in PD pathogenesis. Dr Stanley Appel, Director Johnston Center for Cellular Therapeutics at Houston Methodist Hospital commented: 'The data offer strong insights into how peripheral inflammation is a key driver of the pathophysiology of PD. During the early stages of disease, myeloid cells are anti-inflammatory, but in later stages there is increased oxidative stress and proinflammatory signaling that promote peripheral and CNS dysfunction. The observed correlation of peripheral monocytes with disease burden and progression further supports the proposed dual effect of COYA 302. This therapy is designed to both enhance the anti-inflammatory function of Tregs and suppress the inflammation caused by monocytes and macrophages.' 'Results of this novel research study confirm our findings in other serious neurodegenerative diseases driven by sustained inflammation and strengthen our multitargeted immunomodulatory approach as a strategy for treating severe conditions with high unmet needs' Dr Fred Grossman, Chief Medical Officer, added. Highlights of Study Results This cross-sectional study in peripheral blood monocytes isolated from patients with PD and age- and sex-matched controls showed differential expression of inflammatory, immunoregulatory, and chemotactic receptor transcripts, as summarized below: Upregulation of the pro-inflammatory cytokine interleukin 6 (IL-6) and interleukin 1 beta (IL-1b) transcripts was observed in PD monocytes compared to control monocytes, and its expression increased with advanced stages of PD. The chemokine receptor C-C receptor type 2 (CCR2), which facilitates monocyte migration to sites of inflammation, was upregulated in PD monocytes compared to controls. Additionally, CCR2 expression was increased in early PD and continued to rise with advancing disease stages. Transcripts of the mannose receptor (MRC1/CD206), a marker of alternatively activated (M2) myeloid cells, were upregulated in early-stage PD monocytes but declined with disease progression, resulting in decreased expression in late-stage disease. CD163, a scavenger receptor associated with immunoregulation and protection from oxidative stress, was increased in monocytes from PD patients. CD163 transcripts were low in early-stage PD but increased with disease progression. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A or PGC-1α), an important transcriptional activator, exhibited a slight but non-significant increase in early-stage PD monocytes. However, its transcript levels progressively declined as the disease advanced. Glutathione peroxidase 4 (GPX4), an antioxidant enzyme implicated in PD, was elevated in PD monocytes compared to controls. When stratified by disease stage, GPX4 expression increased early but declined in later stages of disease. Sirtuin 1 (SIRT1) and Sirtuin 3 (SIRT3) are NAD⁺-dependent deacetylases with critical roles in oxidative stress responses, mitochondrial regulation, and inflammation. SIRT1 transcripts were upregulated in PD monocytes relative to controls; expression increased during early and intermediate disease stages but declined with disease progression. Conversely, SIRT3 transcripts were reduced in PD monocytes, with early stage decreases that became more pronounced as disease advanced. About COYA 302 COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. COYA 302 comprises proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig and is being developed for subcutaneous administration for the treatment of patients with ALS. These mechanisms may have additive or synergistic effects. COYA 302 is an investigational product not yet approved by the FDA or any other regulatory agency. About Parkinson's Disease Parkinson's disease is a type of neurologic movement disorder, affecting the brain and causing difficulty with movements, or motor symptoms. It is characterized by its most common motor symptoms - tremors (a form of rhythmic shaking), stiffness or rigidity of the muscles, and slowness of movement (called bradykinesia) - but also manifests in non-motor symptoms including sleep problems, constipation, anxiety, depression, and fatigue, among others, which can be present well before any visible motor symptoms. It is a chronic and progressive condition, meaning that the symptoms become worse over time and can affect the ability to perform common daily activities. There are an estimated 1 million people in the U.S. living with Parkinson's disease and more than 10 million people worldwide. Most people who develop the symptoms of Parkinson's disease do so after the age of 50, but Parkinson's disease can affect younger persons as well. Approximately 10% of Parkinson's diagnoses occur before age 50. 1,2 1. National Institute of Neurological Disorders and Stroke website (accessed July 2025). 2. Parkinson's Foundation website (accessed July 2025). About Coya Therapeutics, Inc. Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ('Tregs') to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. For more information about Coya, please visit Forward-Looking Statements This press release contains 'forward-looking' statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including information concerning our business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
